Compare

MOTS-c vs NAD+

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

82 users report co-tracking this pair (47% of MOTS-c trackers also track NAD+).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

MOTS-c

103 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
182
Mood
55
Focus
174
Sleep quality
32
Lean mass
37

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
98
Fatigue
135
Nausea
139
Water retention
27
Appetite loss
36

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.1–3 mg

0.1–0.2 mg
2
0.2–0.4 mg
5
0.4–0.6 mg
10
0.6–1 mg
20
1–2 mg
15
2–3 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects33mots-c11

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 21 days · Based on 23 repeat reporters

NAD+

865 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
184
Digestive comfort
191
Skin appearance
34
Appetite control
59
Energy
17

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
100
Flushing
90
Headache
179
GI discomfort
55
Dizziness
17

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.025–3 mg

0.025–0.05 mg
9
0.05–0.1 mg
17
0.1–0.2 mg
25
0.2–0.4 mg
28
0.4–0.6 mg
19
0.6–1 mg
15
1–2 mg
10
2–3 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing29stacking12side effects15nad+23

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 30 days · Based on 190 repeat reporters

Sources (14)

Published sources linked on the MOTS-c and NAD+ wiki pages.

  1. PubMed

    MOTS-c is an ancient mitochondrial-encoded regulator of metabolic homeostasis

    Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015

    Source
    Wiki study page →
  2. PubMed

    MOTS-c: A mitochondrial-encoded peptide regulating muscle function

    Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021

    Source
    Wiki study page →
  3. PubMed

    MOTS-c improves insulin sensitivity in mice and humans

    Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    MOTS-c metabolic studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

    Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023

    Source
    Wiki study page →
  6. PubMed

    MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

    Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016

    Source
    Wiki study page →
  7. PubMed

    NAD+ metabolism and its roles in cellular processes during ageing

    Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021

    Source
    Wiki study page →
  8. PubMed

    Safety and efficacy of NAD+ supplementation: a systematic review

    Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021

    Source
    Wiki study page →
  9. PubMed

    NAD+ intermediates: The biology and therapeutic potential

    Yoshino J, Baur JA, Imai SI. Cell Metab. 2018

    Source
    Wiki study page →
  10. PubMed

    Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns

    Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023

    Source
    Wiki study page →
  11. PubMed

    The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

    Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023

    Source
    Wiki study page →